New Clinical Trial Partners to Expand Laboratory Sciences Clinical Sample Analysis Groups - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Clinical Trial Partners to Expand Laboratory Sciences Clinical Sample Analysis Groups



Charles River has established partnerships with Target Health Inc. and Theorem Clinical Research Inc. allow nonclinical testing programs performed by Charles River in bioanalysis, immunogenicity, and immunology to transition to support clinical trials.

Charles River develops and validates assays in support of nonclinical programs. Many of these assays can be transferred and validated for human matrix and subsequently used for analyzing clinical samples.

In a statement, the Charles River reports that these new relationships will allow company scientists to manage clinical sample analysis using defined processes and procedures to improve customer satisfaction.

http://www.criver.com

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here